Immunic, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Immunic, Inc. (IMUX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $6.05 per share for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-04.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2019-03-04
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $6.31, a 24.95% increase year-over-year.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $5.05, a 43.70% decline year-over-year.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $8.97, a 62.12% decline year-over-year.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2015-03-31 was $23.68, a 196.00% increase year-over-year.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2018 was $6.05, a 84.45% increase from fiscal 2017.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $3.28, a 59.46% decline from fiscal 2016.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $8.09, a 2.76% decline from fiscal 2015.
- Immunic, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2015 was $8.32, a 50.62% decline from fiscal 2014.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2018-12-31 | $6.05 10-K · filed 2019-03-04 | |||
| 2018-09-30 | $6.05 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $6.01 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $6.31 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $3.28 10-K · filed 2018-03-13 | |||
| 2017-09-30 | $3.24 10-Q · filed 2017-10-25 | |||
| 2017-06-30 | $3.25 10-Q · filed 2017-08-03 | |||
| 2017-03-31 | $5.05 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $8.09 10-K · filed 2017-03-07 | |||
| 2016-09-30 | $8.12 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $8.25 10-Q · filed 2016-08-02 | |||
| 2016-03-31 | $8.97 10-Q · filed 2016-05-09 | |||
| 2015-12-31 | $8.32 10-K · filed 2016-03-08 | |||
| 2015-09-30 | $21.96 10-Q · filed 2015-11-05 | |||
| 2015-06-30 | $22.98 10-Q · filed 2015-08-06 | |||
| 2015-03-31 | $23.68 10-Q · filed 2015-05-12 | |||
| 2014-12-31 | $16.85 10-K · filed 2015-03-20 | |||
| 2014-09-30 | $15.89 10-Q · filed 2014-11-13 | |||
| 2014-06-30 | $10.22 10-Q · filed 2014-08-07 | |||
| 2014-03-31 | $8.00 10-Q · filed 2014-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B |